Aptus Pharma has informed that it enclosed disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Milly Chetan Lalseta.
The above information is a part of company’s filings submitted to BSE.